Editor's key points † The authors reviewed the literature regarding the effects of beta-blockers during electroconvulsive therapy, in particular, their effects on haemodynamics and seizure attenuation. † Various effects were noted, but a paucity of consistent evidence appears to mandate a prospective study of the subject.
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Electroconvulsive therapy (ECT) is associated with at least transient episodes of hypertension and tachycardia. Beta-blocking agents may be indicated to prevent cardiovascular complications and may shorten seizure duration. This review evaluates studies that used beta-blocking agents during ECT to determine which agent has the most favourable outcomes on cardiovascular variables and seizure duration. A Medline database search was made using the combined keywords 'adrenergic beta-antagonists' and 'electroconvulsive therapy'. The search was restricted to double-blind randomized controlled trials and yielded 29 original studies. With the use of esmolol, significant attenuating effects were found on cardiovascular parameters in the first 5 min after stimulation; its shortening effects on seizure duration may be dose-related. With the use of labetalol, findings on cardiovascular effects were inconsistent during the first minutes after stimulation but were significant after 5 min and thereafter; seizure duration was scarcely studied. Landiolol attenuates heart rate but with inconsistent findings regarding arterial pressure (AP); seizure duration was mostly unaffected. Esmolol appears to be effective in reducing the cardiovascular response, although seizure duration may be affected with higher dosages. Landiolol can be considered a suitable alternative, but effects on AP need further investigation. Labetalol has been studied to a lesser extent and may have prolonged cardiovascular effects. The included studies varied in design, methodology, and the amount of exact data provided in the publications. Further study of beta-blocking agents in ECT is clearly necessary.
Keywords: adrenergic beta-antagonists; electroconvulsive therapy; esmolol; labetalol; landiolol Electroconvulsive therapy (ECT) is considered a highly effective treatment for severe depression, especially in life-threatening cases or when other methods of treatment have failed. 1 2 However, both the stimulus and the induced seizure cause a parasympathetic and sympathetic reaction, respectively.
The first reaction is mediated through stimulation of the vagus nerve and ends when the actual seizure starts, usually within seconds. The second, amplified by the release of catecholamines, may last several minutes. Heart rate (HR) and arterial pressure (AP) increase dramatically and coronary ischaemia may develop in patients at risk. 3 4 Pre-treatment screening helps to identify patients at risk of cardiovascular complications during ECT. In these patients it may be necessary to actively attenuate the cardiovascular response during ECT 5 and, to this end, many agents have been studied. 6 -11 However, these agents either lacked efficiency or have a biological half-life that exceeds the time of one ECT treatment session.
More recently, beta-blocking agents with a short half-life were studied. However, side-effects such as decrease in seizure duration, prolonged cardiovascular depression, and excessive hypotension have been reported.
Results
The search yielded a total of 29 articles. Of these, the following nine articles were excluded from this review. One study explored the response of schizophrenia to the addition of a beta-adrenergic blocking agent, without the use of ECT. 16 One study explored the response of major depressive disorder to the addition of pindolol to ECT: pindolol has a long biological half-life that exceeds the duration of one ECT-treatment session; therefore, we did not consider this study suitable for our review. 17 One study explored the effects of beta-adrenergic blockers on neuroendocrine hormones and another investigated the effects of ECTon neuroendocrine hormones afteradministration of a beta-blocking agent; 18 19 one reported on the effect of esmolol on a processed EEG registration in healthy male patients who did not undergo ECT; 20 one explored the effects of nicardipine in different dosages, both with and without labetalol 10 mg and another study with nicardipine used labetalol as an outcome criterion; 21 22 one was written in Chinese and one was excluded because of concomitant use of nifedipine. 23 24 Of the remaining 20 papers, 9 described one or multiple comparisons between esmolol and placebo; 25 -33 4 publications studied both esmolol and labetalol; 34 -37 1 publication studied esmolol and landiolol; 38 2 publications studied labetalol only; 39 40 and 4 publications described one or more comparisons between landiolol and placebo. 12 41 -43 ECT typically involves multiple treatment-sessions: this allows a cross-over study-design, in which patients serve as their own controls. Many studies adopted this strategy.
In two publications, patients received 1-3 randomized pairs of treatment alternating placebo and intervention: 29 33 their total number of treatment interventions was averaged. Dosages studied are denoted in milligrams per kilogram: if this was not specified in the article, then dosages were calculated for each trial. Table 2 Pre-and post-ECT values for significant differences in AP (mm Hg) or RPP (bpm mm Hg) in the included studies of esmolol. See Table 1 
Continued
Beta-blocking agents during ECT Effects on AP were reported in either systolic arterial pressures or diastolic arterial pressures (SAPs and DAPs, respectively) or mean arterial pressure (MAP, defined as once SAP plus twice DAP, then divided by three). Some studies used rate pressure product (RPP) as an outcome measure, defined as HR times SAP. It was not possible to convert these data into one measure because in most publications insufficient data were provided to do so.
Esmolol
Esmolol was studied in a total of 18 trials (reported in 14 publications): dosages, sample sizes, (average) number of treatment interventions per patient, and results are summarized in Tables 1-3 . Of the above-mentioned 18 trials, the following 12 (reported in 9 publications) studied both cardiovascular parameters and seizure duration.
(1) Howie and colleagues 25 In the remaining six trials (reported in five publications), either cardiovascular variables or seizure duration (but not both together) was studied. Table 4 Pre-and post-ECT values for significant differences in HR (bpm) in the included studies of labetalol. See Table 1 
Labetalol
Labetalol was studied in six publications. In four of those, seizure duration was not an outcome criterion. 34 -36 40 Results are summarized in Tables 4-6. (1) Castelli and colleagues 34 
Landiolol
Landiolol was studied in nine trials (reported in five publications); the results are summarized in Tables 7-9. (1) Sakamoto and colleagues 12 reported on a randomized, placebo-controlled, double-blind cross-over study with Table 7 Pre-and post-ECT values for significant differences in HR (bpm) in the included studies of landiolol. See Table 1 
Discussion
With esmolol, the acute increase in HR was consistently attenuated. Also, attenuation of the increase in SAP, MAP, and RPP were consistently significant from a dosage of 1.0 mg kg 21 onward. Increase in DAP was consistently attenuated from a dosage of 2.1 mg kg 21 onwards. Labetalol was studied to a limited extent. Findings on cardiovascular effects were inconsistent in the first minutes after stimulation. Significant effects are reported at 5, 10, and 30 min after stimulation. This can be attributed to the longer half-life of labetalol. Landiolol was created by modifying the chemical structure of esmolol and was found to be eight times more potent in cardioselectivity compared with esmolol. 44 With landiolol over 0.125 mg kg 21 significant effects were found in attenuating the increase in HR. Findings on AP are inconsistent. This may be partly because of the limited amount of trials and the different outcome measures used. However, attenuating effects on both HR and AP are strongly preferred in order to prevent myocardial ischaemia. In many studies, if a significant difference in cardiovascular variables was found, measures were often still within an acceptable range. One may thus debate the clinical relevance of some of these differences. Multiple studies excluded patients with an elevated risk of cardiovascular events. Especially in healthy subjects, HR and AP may be considered indirect measures for cardiovascular status; however, these are the only cardiovascular parameters that were consistently reported. Only three studies included ECG-abnormalities as outcome measures. 33 40 42 Respectively, in these three studies, esmolol 2.9 mg kg 21 was not found to reduce the incidence of post-ECT ischaemia or arrhythmia; the frequency of atrial arrhythmias and premature ventricular contractions were significantly reduced with labetalol 0.06 mg kg 21 and the increase in corrected QT caused by ECT was smaller with landiolol 0.280 mg kg
21
, all compared with placebo. With esmolol, a dose-related effect on seizure duration may exist. Six of 10 trials found a significant shortening of clinical seizure duration, but only three found a significant effect on EEG. The implications of these differences remain to be elucidated. Furthermore, four of the trials that found a significantly shortened clinical seizure duration, and all three that found a significant reduction on EEG, still found a seizure duration of over 30 s in the intervention groups. Since 30 s is universally accepted as an adequate seizure duration, the clinical implications of these findings may be small. 45 Only two publications on labetalol studied seizure duration: one study did and the other did not find a significant shortening effect. The significantly shorter duration still lasted longer than 30 s. Only one of eight trials found a significant shortening of clinical seizure duration with landiolol. Quantitative analysis of the data provided was not possible because of differences in design and methodology between the studies (e.g. randomization, dosing, and outcome measures). Although many relevant publications included a graph of the cardiovascular parameters, exact data were often lacking. Co-variables such as continuous psychopharmacological treatment during ECTand electrode placement, if mentioned, varied between and (sometimes) also within the studies.
The use of a beta-blocking agent with ECT should be considered in the context of a full evaluation of each patient's cardiovascular risk, prior to ECT. 46 47 In individual cases, prevention of tachycardia or hypertension may be required. If the use of a beta-blocking agent is indicated, then esmolol seems to be the most favourable agent; it has been studied relatively often and the reduction in seizure duration which may be found in higher dosages may be of limited clinical importance. Landiolol can be considered a suitable alternative, but its effects on AP need further exploration. Since labetalol has been studied to a lesser extent and has a longer biological half-life, it may be considered a less favourable option compared with both other agents. Since electrode placement may affect treatment adequacy and since esmolol may shorten seizure duration (thereby also possibly affecting treatment adequacy), it seems advisable to use bilateral electrode placement in patients with cardiovascular risk factors and standard esmolol during each session.
More research is required, in which the effects of esmolol on seizure duration and the effects of landiolol on both cardiovascular variables and seizure duration would be of particular interest. To allow a quantitative meta-analysis in the future, more exact data are needed with respect to outcome measures, including standard errors, accurate P-values, 95% confidence intervals, or both.
